市場調查報告書
商品編碼
1497663
生物標記市場:按產品/服務、類型、疾病、應用分類 - 全球預測 2024-2030Biomarkers Market by Product & Service (Consumables, Services, Software), Type (Efficacy Biomarkers, Safety Biomarkers, Validation Biomarkers), Disease, Application - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年生物標記市場規模為525億美元,預計2024年將達596.9億美元,2030年將達到1329.8億美元,複合年成長率為14.19%。
生物標記物也稱為生物標記,是生物狀況或狀況的可測量指標,通常在體液和組織中被檢測和量化。由於它可以反映各種生理和病理過程的存在,因此在醫學領域中廣泛應用,如診斷疾病、預測治療效果、監測疾病進展等。生物標記的廣泛使用主要是由於慢性病盛行率的不斷上升以及對個人化醫療的日益重視,個人化醫療根據個人特徵、行為和風險因素制定治療方案。然而,生物標記開發的挑戰包括發現和檢驗的高成本和複雜性、監管障礙以及需要強大的臨床檢驗以確保可靠性和有效性。儘管存在這些挑戰,針對新出現的健康威脅的新生物標記的開發、藥物開發過程中對生物標記的關注以及人工智慧的整合以改善生物標記的發現和應用仍在繼續,為更準確、更有效的醫療保健解決方案鋪平了道路。
主要市場統計 | |
---|---|
基準年[2023] | 525億美元 |
預測年份 [2024] | 596.9億美元 |
預測年份 [2030] | 1329.8億美元 |
複合年成長率(%) | 14.19% |
區域洞察
由於先進的醫療基礎設施和研發投資,美洲生物標記市場呈現強勁成長。美國透過在臨床實踐中大規模採用生物標記以及對生物標記研究的強力的機構支持,為這一成長做出了重大貢獻。此外,慢性病盛行率的增加和對個人化醫療的濃厚興趣是推動市場成長的主要因素。由於高額醫療保健支出和較早採用新技術,歐洲市場呈現穩定成長。由於醫療基礎設施的改善以及對個人化醫療益處的認知不斷提高,中東和非洲顯示出成長潛力。由於經濟的快速開拓、醫療保健支出的增加以及政府對醫療保健系統現代化的努力,亞太地區的生物標記市場呈現快速成長。人口成長和疾病發病率增加促進了生物標記的採用。此外,該地區生物技術公司和研究機構的擴張進一步支持了成長。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在生物標記物市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對生物標記物市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該行業競爭性質的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在生物標記市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[195 Pages Report] The Biomarkers Market size was estimated at USD 52.50 billion in 2023 and expected to reach USD 59.69 billion in 2024, at a CAGR 14.19% to reach USD 132.98 billion by 2030.
Biomarkers, also known as biological markers, a measurable indicators of some biological state or condition, often detected and quantified in body fluids or tissues. They are extensively used in medical science for diagnosing diseases, predicting treatment response, and monitoring the progress of disease, owing to their ability to reflect the presence of various physiological or pathological processes. The expansion of their use is primarily driven by the increasing prevalence of chronic diseases and a growing appreciation for personalized medicine, which tailors treatment to individual characteristics, behaviors, and risk factors. However, challenges in biomarker development include the high cost and complexity of discovery and validation, along with regulatory hurdles and the necessity for robust clinical validation to ensure reliability and efficacy. Despite these challenges, the development of novel biomarkers for emerging health threats, enhanced focus on biomarkers in drug development processes, and the integration of artificial intelligence to improve biomarker discovery and application pave the way for more precise and effective healthcare solutions.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 52.50 billion |
Estimated Year [2024] | USD 59.69 billion |
Forecast Year [2030] | USD 132.98 billion |
CAGR (%) | 14.19% |
Regional Insights
The biomarker market in the Americas is showing robust growth, with the presence of advanced healthcare infrastructure and investment in research and development. The United States is the major contributor to this growth, driven by the large-scale implementation of biomarkers in clinical practices and strong support from government entities for biomarker research. Additionally, the increasing prevalence of chronic diseases and a strong focus on personalized medicine are major factors propelling market growth. Europe is displaying steady market growth owing to high healthcare spending and early adoption of new technologies. The Middle East and Africa are showing growth potential due to improving healthcare infrastructure and growing awareness about the benefits of personalized medicine. Asia-Pacific showcases rapid growth in the biomarker market, facilitated by rapid economic development, increasing healthcare expenditure, and government initiatives aimed at modernizing healthcare systems. Growing populations and increasing incidence of diseases contribute to the adoption of biomarkers. Moreover, the expansion of biotechnology companies and research institutions in this region further supports the growth.
Market Insights
The market dynamics represent an ever-changing landscape of the Biomarkers Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biomarkers Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biomarkers Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Owlstone Medical's Novel Initiatives Receive the Bill & Melinda Gates Foundation Funding
Owlstone Medical has received significant financial funding from the Bill & Melinda Gates Foundation to enhance early disease detection using its innovative Breath Biopsy platform. This includes a USD 5 million equity investment and an additional USD 1.5 million in grant funding. The grant is focused on identifying volatile organic compound (VOC) biomarkers for tuberculosis (TB) and human immunodeficiency virus (HIV). [Published On: 2024-04-25]
Pioneering Research Collaboration to Enhance Treatment for Metastatic Colorectal Cancer
The National Comprehensive Cancer Network (NCCN) has collaborated with Fight Colorectal Cancer (Fight CRC) and Pfizer to provide funding aimed at advancing biomarker-directed therapies for metastatic colorectal cancer. This significant financial support is designated for innovative clinical studies that are focused on identifying and utilizing biomarkers to improve the effectiveness and precision of treatments for patients battling this advanced stage of colorectal cancer. [Published On: 2023-08-09]
FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
The U.S. Food and Drug Administration (FDA) has introduced a pivotal pilot program focused on refining the integration of specific oncology drugs with their corresponding in-vitro diagnostic tests. This initiative primarily addresses the critical use of laboratory-developed tests (LDTs) to identify specific biomarkers used for selecting cancer treatment. The program aims to establish and make public the minimum performance characteristics necessary for diagnostic tests utilized in clinical trials. [Published On: 2023-06-21]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biomarkers Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Abcam PLC, APIS Assay Technologies Limited, Augurex Life Sciences Corp, Bio-Rad Laboratories, Inc., BioAgilytix, Biocrates Life Sciences AG, Biofourmis Inc., Biognosys AG, BioStarks, Charles River Laboratories, Inc., Elo Health, Inc., F. Hoffmann-La Roche, Ltd., Merck KgaA, Nightingale Health Plc, Owkin Inc., Owlstone Medical Limited, PerkinElmer, Inc., Personalis, Inc., Proteomedix AG, QIAGEN GmbH, Siemens Healthineers AG, Sino Biological Inc., Thermo Fisher Scientific, Inc., and VivoSense, Inc.
Market Segmentation & Coverage